Simplify Logo
Becton Dickinson

Becton Dickinson

Global medical devices and diagnostics provider

Marketing Director - Strategic Customer Group

Full-TimeUpdated on 9/19/2026
No salary listed
Expert
Bachelor's, MBA
Franklin Lakes, NJ, USA
In Person

In-office role in Franklin Lakes, New Jersey.

About the job

Requirements
  • At least 12 years of experience in business-to-business marketing, with significant experience in healthcare, medical technology, or health information technology.
  • Deep command of integrated marketing communications disciplines, including brand strategy, content marketing, digital demand generation, account-based marketing, event marketing, and sales enablement.
  • Proven experience developing executive-level content and thought leadership programs that influence C-suite audiences and enterprise buying decisions.
  • Fluency in campaign performance metrics, pipeline attribution, and return on investment measurement, with familiarity with marketing technology stacks.
  • Track record of leading through influence in highly matrixed organizations and aligning senior stakeholders across business units, sales, and strategy without direct authority.
  • Understanding of enterprise procurement dynamics, value analysis committees, and system-level decision-making is essential.
  • A bachelor's degree is required.
Responsibilities
  • Define and steward BD's brand positioning within the U.S. health system segment and translate enterprise-wide brand architecture into a distinct Strategic Customer Group narrative.
  • Lead development of an integrated marketing communications framework covering content, digital, events, paid media, public relations, and field communications.
  • Drive thought leadership strategy using third-party research, proprietary data, and clinical evidence.
  • Align Strategic Customer Group brand voice with BD's corporate communications and investor relations narrative.
  • Design and execute account-based marketing demand-generation strategies targeting priority integrated delivery network and strategic health system accounts.
  • Build and optimize a multi-channel campaign engine, content syndication, event marketing, and direct outreach.
  • Own the executive content strategy, including C-suite presentations, white papers, case studies, return-on-investment frameworks, and digital assets.
  • Build a repeatable content architecture with personas mapped to buying stages, message hierarchies, and proof-point libraries.
  • Design executive briefings, advisory boards, hosted forums, and other immersive experiences for health system leadership.
  • Develop digital engagement infrastructure including a website, personalized email journeys, and gated content hubs.
  • Orchestrate integrated marketing strategies across Medical Essentials, Connected Care, and Interventional.
  • Translate complex, multi-product portfolio stories into modular, audience-specific messaging for enterprise accounts.
  • Partner with Product Marketing leaders across business units to ground Strategic Customer Group messaging in product proof points and competitive differentiation.
  • Function as the enterprise marketing leader for the Strategic Customer Group by influencing, aligning, and elevating marketing professionals across business units and functions.
  • Establish the Strategic Customer Group as an internal center of excellence by publishing frameworks, playbooks, and standards.
  • Institutionalize rapid iteration, performance analytics, and feedback loops for the Strategic Customer Group marketing team.
  • Personally develop content, shape messaging, manage agency partners, and set direction for broader marketing work.
  • Apply Lean processes to simplify work, reduce waste, and accelerate impact.
  • Set measurable goals, track progress rigorously, and deliver marketing outcomes.
Desired Qualifications
  • Experience marketing into integrated delivery networks, group purchasing organizations, or integrated health systems.
  • An MBA or advanced degree in marketing, communications, or healthcare administration.
  • Benchmarking against best-in-class business-to-business healthcare marketing communications programs.

About the company

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q3 FY2026 revenue reached $5.0 billion, with adjusted EPS of $3.23.
  • BD completed PREVENT trial enrollment in August 2026, advancing Phasix label expansion.
  • July 2026 EMS semaglutide launch expands BD's GLP-1 delivery platform in Brazil.

What critics are saying

  • July 31, 2026 needle-set recall caused four deaths and 45 serious injuries.
  • BD carried about $1.7 billion legal accruals in May 2026, including ports and hernia claims.
  • FDA-requested ship holds on ChloraPrep and PurPrep signal manufacturing controls and warning-letter risk.

What makes Becton Dickinson unique

  • BD spans needles, drug delivery, interventional devices, and diagnostics at global scale.
  • BD Vystra and EMS semaglutide show durable pen-platform expertise across injectable medicines.
  • BD's Phasix, CIRSE training, and tissue-regeneration pipeline reinforce recurring surgeon and hospital relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
Yahoo Finance
Aug 18th, 2026
Wall Street analysts give Becton, Dickinson a 'moderate buy' rating despite 12% earnings decline forecast

Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".

PR Newswire
Aug 17th, 2026
BD names Gary Sorsher chief quality officer as Jeff Silvestri retires after 25 years

BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.

MedTech Dive
Aug 13th, 2026
BD fully enrolls trial of resorbable mesh for hernia prevention.

BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."

Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.